|
Biocon Biologics in its first anniversary as a fully integrated, global biosimilars company dedicated to expanding access to high-quality affordable biologic medicines for patients worldwide. This marks its emergence as a global enterprise operating in over 120 countries, supported by a diverse, multicultural workforce spanning more than 30 nationalities.
Shreehas Tambe, CEO & managing director, Biocon Biologics Limited, said: “We have successfully transformed the organization from a two-country operation focused on development and manufacturing, to a fully integrated company with a strong commercial engine. We have laid a strong foundation for accelerated business growth that will unlock value for the company and all our stakeholders."
A Three-Stage Strategy: Preserve, Consolidate, Accelerate approach has helped to the preservation of value during the business transition in 2023, followed by consolidation of the business in 2024 while achieving profitable growth. The company has now stepped into the final stage of accelerated business growth in 2025 and beyond, he added.
Following completion of the acquisition in November 2022, Biocon Biologics successfully navigated the complexities of integrating a global business which can often take 2-3 years and focused on preserving the value for all stakeholders.
The Bengaluru-based company surpassed $1 billion revenue milestone. Leveraging its own field force and strategic partnerships, the company expanded patient reach, and forged long-term, strategic commercial collaborations with the intent to serve more patients globally. In doing so, it was also able to unlock value in its product brands in several markets, including India.
It also had made over 60 commercial launches of existing products, 2 key new approvals between January and December 2024 in emerging and advanced markets. It is also positioned as Asia’s 1st bond issuance by a biopharma company after it was listed on the Singapore Stock Exchange. It oversubscribed more than threefold, this issuance which according to Biocon Biologics is the largest debut issuance by an Indian company in the past decade. This has allowed the company to improve its liquidity profile, provide financial flexibility and the opportunity to re-invest the cash into the business to drive growth, stated its communication note.
Further, the company said that Year 2025 marks the beginning of a new phase. Here it is now focusing on accelerating growth by launching new products in existing markets and introducing existing products to new territories. Over the next two to three years, it plans three global launches (bAflibercept, bUstekinumab, and bDenosumab) and five US launches (bAspart, bBevacizumab, bAflibercept, bUstekinumab, and bDenosumab). This accelerated growth aims to propel Biocon Biologics to be among the top 3 biosimilars companies globally.
|